title: [Efficacy of vitaprost forte in patients with prostatic adenoma].
abstract: The trial of a new bioregulatory peptide vitaprost forte (100 mg rectal suppositoria) in 30 patients with prostatic adenoma demonstrated that this drug attenuates clinical symptoms of the disease, improves quality of life, uroflowmetric parameters and reduces size of the prostate. Vitaprost forte is more effective in patients with prostatic adenoma in combination with chronic prostatitis, has antiaggregant and anticoagulant properties, stimulates synthesis of antihistamine and antiserotonine antibodies, improves microcirculation in the prostate resulting in regressioin of edema, activity of inflammation in prostatic diseases.
authors.forename: A M
authors.initials: AM
authors.lastname: Miller
authors.forename: V P
authors.initials: VP
authors.lastname: Iaroshenko
authors.forename: P V
authors.initials: PV
authors.lastname: Soroka
authors.forename: E Iu
authors.initials: EIu
authors.lastname: Stakhnev
mesh_terms: D002908:Chronic Disease; D004487:Edema / Q000150:complications / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D006801:Humans; D007249:Inflammation / Q000150:complications / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D008297:Male; D008833:Microcirculation / Q000187:drug effects; D008875:Middle Aged; D010455:Peptides / Q000008:administration & dosage*; D011470:Prostatic Hyperplasia / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D011472:Prostatitis / Q000150:complications / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology
chemical_list: D010455:Peptides; C524164:Vitaprost